Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Short Interest Update

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) was the recipient of a significant growth in short interest in the month of October. As of October 15th, there was short interest totalling 60,200 shares, a growth of 29.2% from the September 30th total of 46,600 shares. Currently, 2.5% of the company’s shares are sold short. Based on an average trading volume of 3,380,000 shares, the days-to-cover ratio is presently 0.0 days.

Catheter Precision Stock Down 2.0 %

VTAK traded down $0.01 during midday trading on Tuesday, reaching $0.55. 710,061 shares of the company’s stock traded hands, compared to its average volume of 1,078,108. Catheter Precision has a 52 week low of $0.31 and a 52 week high of $8.40.

Catheter Precision (NYSEAMERICAN:VTAK) last posted its earnings results on Wednesday, August 14th. The company reported ($5.57) earnings per share (EPS) for the quarter. Catheter Precision had a negative net margin of 2,176.83% and a negative return on equity of 50.02%. The business had revenue of $0.09 million for the quarter. Research analysts anticipate that Catheter Precision will post -8.7 EPS for the current year.

About Catheter Precision

Catheter Precision, Inc designs, manufactures, and sells medical technologies for the field of cardiac electrophysiology (EP) in the United States. The company’s lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures.